Major Shareholder of KYMERA THERAPEUTICS Sells Over 21,000 Shares of Stock
January 18, 2023
Trending News ☀️
Kymera Therapeutics Stock Fair Value – KYMERA ($NASDAQ:KYMR) Therapeutics is a biopharmaceutical company that is focused on developing small molecule therapies for genetic diseases. It is located in Cambridge, Massachusetts and is led by a team of seasoned industry veterans. Recently, the company’s major shareholder sold a total of 21,683 shares of the company’s stock. KYMERA has developed its own proprietary platform to discover and develop innovative medicines to treat genetic diseases. This platform uses advanced technologies such as gene editing and artificial intelligence to identify potential drug targets and accelerate the development of novel therapies. The company is currently focused on developing treatments for rare diseases that have limited or no treatment options. The company is also actively engaged in research and development collaborations with leading biopharmaceutical companies, academic institutions and non-profit organizations. It has collaborations with companies such as Novartis, Gilead Sciences, and Pfizer. KYMERA’s research and development efforts are aimed at developing therapies for various diseases such as cystic fibrosis, sickle cell disease, and Huntington’s disease. The recent sale of 21,683 shares of stock by the company’s major shareholder could signal a shift in the company’s focus. It is possible that the shareholder may be looking to diversify their investments or to capitalize on the recent growth in the company’s stock price.
However, it is also possible that the shareholder believes there is still more upside potential in the stock. Regardless of the reason for the sale, it is important to note that KYMERA Therapeutics remains focused on developing innovative therapies to address unmet medical needs. The company is well-positioned to take advantage of its proprietary platform and collaboration partnerships to bring these potential treatments to patients in need.
Share Price
The transaction has been reported to the Securities and Exchange Commission, or SEC. This news comes on the heels of what has been overall positive media exposure for the company. KYMERA THERAPEUTICS stock opened at $35.0 and closed at $34.6, up by 0.2% from prior closing price of 34.5. Despite this slight increase, the stock has experienced a small drop in the past months as traders have shown some hesitancy about investing in the company. This suggests that KYMERA THERAPEUTICS is in a good position to weather any economic downturns and continue to pursue its research and development activities. As for the recent stock sale by the major shareholder, it is unclear why it was made or who the buyer was.
However, given that KYMERA THERAPEUTICS is an innovative biotech company with promising prospects, it could be that the shareholder saw an opportunity to make a profitable return on their investment. Overall, KYMERA THERAPEUTICS is an exciting company to watch as it continues to make waves in the biotech industry. With its strong financials and innovative research and development activities, the company is well-positioned to continue making strides in the years to come. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 45.96 | -153.84 | -137.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…
| Operations | Investing | Financing |
| -151.9 | 2.17 | 153.1 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 638.47 | 125.59 | 9.37 |
Key Ratios Snapshot
Some of the financial key ratios for Kymera Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -137.4% |
| FCF Margin | ROE | ROA |
| -336.9% | -21.1% | -15.0% |
VI Analysis – Kymera Therapeutics Stock Fair Value
KYMERA THERAPEUTICS is a biopharmaceutical company with a strong long-term potential. By using the VI app, it’s simple to analyze the fundamentals of the company and determine the fair value of its stock. According to the VI Line, the fair value of a KYMERA THERAPEUTICS share is approximately $32.3. However, the current market price for its stock is $34.6, which is 7% higher than its fair value. This indicates that the stock is slightly overvalued at the moment. Nevertheless, with the company’s strong fundamentals and long-term potential, investors may still consider purchasing its stock as a viable investment option. More…
VI Peers
The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.
– Abionyx Pharma ($LTS:0RAG)
Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.
– Prestige BioPharma Ltd ($KOSE:950210)
Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).
Summary
Investing in Kymera Therapeutics can be a risky but potentially rewarding venture. However, overall media exposure has been positive, suggesting that while there is risk involved, the company may be able to turn things around and provide investors with good returns. It is important to do careful research before investing in Kymera Therapeutics, as the share price can be volatile and the risk of losses can be high.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
